Drugs

, Volume 72, Issue 3, pp 327–337

Pharmacokinetics of Intravenous Ibuprofen

Implications of Time of Infusion in the Treatment of Pain and Fever
Review Article

Abstract

Intravenous NSAIDs are playing an increasingly large role in analgesia, anti-inflammation and antipyresis in the hospitalized setting. For many years, ketorolac was the only intravenous NSAID available in the US, but in 2009 intravenous ibuprofen was approved by the US FDA for the treatment of pain and fever in adults. In developing intravenous ibuprofen, a range of times of infusion and dosing levels have been utilized and compared with the oral route of administration. The earliest studies utilized a 60-minute infusion, and later a 30-minute infusion was used for the pivotal/registration studies demonstrating efficacy and safety. Another recent trial in healthy volunteers demonstrated a safe and tolerable rapid infusion (5–7 minute) of intravenous ibuprofen. The pharmacokinetic data from all of the clinical trials on 400 and 800 mg doses of intravenous ibuprofen were compiled, and pharmacokinetic modelling was utilized to simulate any data not acquired in the clinical studies. The pharmacokinetic profile of the following doses was modelled: 30-minute infusion of 800 mg intravenous ibuprofen, 5- to 7-minute infusion of 400 mg intravenous ibuprofen and 400 mg ibuprofen oral tablet. These pharmacokinetic analyses revealed that, in general, maximum plasma concentration (Cmax) decreases considerably as the length of the infusion increases and that an oral dose is not able to achieve the Cmax level of any intravenous dose. For the rapid infusion, Cmax was twice that of the oral dose and, as expected, time to Cmax (tmax) was much more rapid than with the oral dose. However, the oral dose still maintained virtually 100% oral bioavailability. The efficacy of intravenous ibuprofen in terms of pain and fever has also been studied and this review found the drug to be efficacious for both indications. Future areas of study should include assessment of the analgesic and antipyretic efficacy of a rapid (5- to 10-minute) infusion and further assessment of pre-emptive administration of intravenous ibuprofen as part of a multimodal analgesic approach in the surgical setting.

References

  1. 1.
    Caldolor (ibuprofen) injection prescribing information. Nashville (TN): Cumberland Pharmaceuticals Inc., 2009Google Scholar
  2. 2.
    Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997 Mar 27; 336(13): 912–8CrossRefGoogle Scholar
  3. 3.
    Southworth S, Peters J, Rock A, et al. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain. Clin Ther 2009 Sep; 31(9): 1922–35PubMedCrossRefGoogle Scholar
  4. 4.
    Kroll PB, Meadows L, Rock A, et al. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen (i.v.-ibuprofen) in the management of postoperative pain following abdominal hysterectomy. Pain Pract 2011 Jan–Feb; 11(1): 23–32PubMedCrossRefGoogle Scholar
  5. 5.
    Singla N, Rock A, Pavliv L. A multi-center, randomized, double-blind placebo-controlled trial of intravenousibuprofen (IV-ibuprofen) for treatment of pain in postoperative orthopedic adult patients. Pain Med 2010 Aug; 11(8): 1284–93PubMedCrossRefGoogle Scholar
  6. 6.
    Morris PE, Promes JT, Guntupalli KK, et al. A multicenter, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults. Crit Care 2010; 14(3): R125PubMedCrossRefGoogle Scholar
  7. 7.
    Krudsood S, Tangpukdee N, Wilairatana P, et al. Intravenous ibuprofen (IV-ibuprofen) controls fever effectively in adults with acute uncomplicated Plasmodium falciparum malaria but prolongs parasitemia. Am J Trop Med Hyg 2010 Jul; 83(1): 51–5PubMedCrossRefGoogle Scholar
  8. 8.
    Pavliv L, Voss B, Rock A. Pharmacokinetics, safety, and tolerability of a rapid infusion of i.v. ibuprofen in healthy adults. Am J Health Syst Pharm 2011 Jan 1; 68(1): 47–51CrossRefGoogle Scholar
  9. 9.
    Promes JT, Safcsak K, Pavliv L, et al. A prospective, multicenter, randomized, double-blind trial of IV ibuprofen for treatment of fever and pain in burn patients. J Burn Care Res 2011 Jan–Feb; 32(1): 79–90PubMedCrossRefGoogle Scholar
  10. 10.
    Bookstaver PB, Miller AD, Rudisill CN, et al. Intravenous ibuprofen: the first injectable product for the treatment of pain and fever. J Pain Res 2010; 3: 67–79PubMedCrossRefGoogle Scholar
  11. 11.
    Data on file, Cumberland Pharmaceuticals Inc., 2011 Mar 30Google Scholar
  12. 12.
    Trotman RL, Williamson JC, Shoemaker DM, et al. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005 Oct 15; 41(8): 1159–66PubMedCrossRefGoogle Scholar
  13. 13.
    Davies NM. Clinical pharmacokinetics of ibuprofen: the first 30 years. Clin Pharmacokinet 1998 Feb; 34(2): 101–54PubMedCrossRefGoogle Scholar
  14. 14.
    Martin W, Koselowske G, Toberich H, et al. Pharmacokinetics and absolute bioavailability of ibuprofen after oral administration of ibuprofen lysine in man. Biopharm Drug Dispos 1990 Apr; 11(3): 265–78PubMedCrossRefGoogle Scholar
  15. 15.
    Cumberland Pharmaceuticals. Surveillance trial to evaluate a shortened infusion time of intravenous ibuprofen [ClinicalTrials.gov identifier NCT01334944]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 11]
  16. 16.
    Cumberland Pharmaceuticals. Surgical surveillance trial to evaluate a shortened infusion time of intravenous ibuprofen [ClinicalTrials.gov identifier NCT01334957]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 11]
  17. 17.
    St. Barnabas Medical Center. Does preoperative caldolor decrease the requirement for postoperative narcotics [ClinicalTrials.gov identifier NCT01297829]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 10]
  18. 18.
    University of Medicine and Dentistry New Jersey. IV ibuprofen for post-electroconvulsive therapy myalgia [ClinicalTrials.gov identifier NCT01200069]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 10]
  19. 19.
    Thomas Jefferson University. A double-blind, placebo-controlled pilot study to collect and evaluate data on the use of intravenous ibuprofen in the treatment of an acute migraine attack [ClinicalTrials.gov identifier NCT01230411]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 10]
  20. 20.
    Cumberland Pharmaceuticals. Safety and efficacy of intravenous ibuprofen for treatment of pain in pediatric patients undergoing tonsillectomy [ClinicalTrials.gov identifier NCT01332253]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 10]
  21. 21.
    Woolf CJ, Chong MS. Preemptive analgesia: treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 1993 Aug; 77(2): 362–79PubMedGoogle Scholar
  22. 22.
    Kissin I. Preemptive analgesia: why its effect is not always obvious. Anesthesiology 1996 May; 84(5): 1015–9PubMedCrossRefGoogle Scholar
  23. 23.
    Ong CK, Lirk P, Seymour RA, et al. The efficacy of preemptive analgesia for acute postoperative pain management: a meta-analysis. Anesth Analg 2005 Mar; 100(3): 757–73PubMedCrossRefGoogle Scholar
  24. 24.
    Duellman TJ, Gaffigan C, Milbrandt JC, et al. Multi-modal, pre-emptive analgesia decreases the length of hospital stay following total joint arthroplasty. Orthopedics 2009 Mar; 32(3): 167PubMedCrossRefGoogle Scholar
  25. 25.
    Cumberland Pharmaceuticals. Safety, efficacy, and pharmacokinetic study of intravenous ibuprofen in pediatric patients [ClinicalTrials.gov identifier NCT01002573]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2012 Jan 11]
  26. 26.
    Laska EM, Sunshine A, Marrero I, et al. The correlation between blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther 1986 Jul; 40(1): 1–7PubMedCrossRefGoogle Scholar
  27. 27.
    Olson NZ, Otero AM, Marrero I, et al. Onset of analgesia for liquigel ibuprofen 400 mg, acetaminophen 1000 mg, ketoprofen 25 mg, and placebo in the treatment of postoperative dental pain. J Clin Pharmacol 2001 Nov; 41(11): 1238–47PubMedCrossRefGoogle Scholar
  28. 28.
    Packman B, Packman E, Doyle G, et al. Solubilized ibuprofen: evaluation of onset, relief, and safety of a novel formulation in the treatment of episodic tension-type headache. Headache 2000 Jul–Aug; 40(7): 561–7PubMedCrossRefGoogle Scholar
  29. 29.
    Daniels S, Reader S, Berry P, et al. Onset of analgesia with sodium ibuprofen, ibuprofen acid incorporating poloxamer and acetaminophen: a single-dose, double-blind, placebo-controlled study in patients with postoperative dental pain. Eur J Clin Pharmacol 2009 Apr; 65(4): 343–53PubMedCrossRefGoogle Scholar
  30. 30.
    Kauffman RE, Nelson MV. Effect of age on ibuprofen pharmacokinetics and antipyretic response. J Pediatr 1992 Dec; 121(6): 969–73PubMedCrossRefGoogle Scholar
  31. 31.
    Kelley MT, Walson PD, Edge JH, et al. Pharmacokinetics and pharmacodynamics of ibuprofen isomers and acetaminophen in febrile children. Clin Pharmacol Ther 1992 Aug; 52(2): 181–9PubMedCrossRefGoogle Scholar
  32. 32.
    Nielsen JC, Bjerring P, Arendt-Nielsen L, et al. A double-blind, placebo controlled, cross-over comparison of the analgesic effect of ibuprofen 400 mg and 800 mg on laser-induced pain. Br J Clin Pharmacol 1990 Nov; 30(5): 711–5PubMedCrossRefGoogle Scholar
  33. 33.
    Ceppi Monti N, Gazzaniga A, Gianesello V, et al. Activity and pharmacokinetics of a new oral dosage form of soluble ibuprofen. Arzneimittel-Forschung 1992 Apr; 42(4): 556–9PubMedGoogle Scholar
  34. 34.
    Aronoff DM, Neilson EG. Antipyretics: mechanisms of action and clinical use in fever suppression. Am J Med 2001 Sep; 111(4): 304–15PubMedCrossRefGoogle Scholar
  35. 35.
    Grosser T, Smyth E, FitzGerald GA. Anti-Inflammatory, Antipyretic, and Analgesic Agents;Pharmacotherapy of Gout. In: Brunton L, Chabner B, Knollman B. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. Columbus (OH): McGraw-Hill Companies, Inc., 2011: 959–1004Google Scholar
  36. 36.
    Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999 Jun 22; 96(13): 7563–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  1. 1.Department of AnesthesiologyAlbany Medical CenterAlbanyUSA
  2. 2.Cumberland Pharmaceuticals Inc.NashvilleUSA

Personalised recommendations